UK – NICE recommends STADA and Calliditas’ Kinpeygo to treat rare kidney disease IgAN

The National Institute for Health and Care Excellence (NICE) has recommended STADA and Calliditas Therapeutics’ targeted-release Kinpeygo (budesonide) to treat a subset of patients with IgA nephropathy (IgAN), a rare kidney disease.

Affecting approximately 14,000 people in England, IgAN occurs when IgA accumulates in the kidneys, causing inflammation and scarring, which can lead to kidney failure.

Patients can experience a broad range of symptoms, including bone and joint pain, fatigue and muscle weakness, and as the condition progresses, chronic kidney disease and associated infections can lead to hospitalisation…